Search clinical trials for: Interferon omega 1

Total 16942 results

Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability

Relapsing Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®) (BRAVO)

Multiple Sclerosis

United States, Bulgaria, Croatia, Czechia, Estonia, Georgia, Germany, Israel, Italy, Lithuania, North Macedonia, Poland, Puerto Rico, Romania, Russian Federation, Slovakia, South Africa, Spain, Ukraine
Merck KGaA, Darmstadt, Germany
Merck Serono Middle East FZ LLC

Completed

Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)

Relapsing Multiple Sclerosis (RMS)

Bulgaria, Poland, Argentina, Hungary, Korea, Republic of, Saudi Arabia, Egypt, Algeria, Bahrain, Iran, Islamic Republic of, Kuwait, Lebanon, Morocco
Bayer

Completed

Betaferon Use in Children and Adolescents With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Bayer

Completed

Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon (BetaSleep)

Multiple Sclerosis

Germany
Beth Israel Deaconess Medical Center
Biogen

Completed

Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis (CHAMPIONS10)

Multiple Sclerosis | Optic Neuritis | Transverse Myelitis | Acute Brainstem/Cerebellar Syndrome

United States, Canada
Tianjin SinoBiotech Ltd.

Completed

Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Chinese Healthy Volunteers

Healthy

China
Yonsei University

Completed

A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon

Chronic Hepatitis B

Korea, Republic of
Ohio State University Comprehensive Cancer Center

Completed

Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma

Melanoma

United States
Bayer

Completed

Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors (POR-BetaPlus)

Secondary Progressive Multiple Sclerosis (SPMS) | Relapsing Remitting Multiple Sclerosis (RRMS)

Portugal
Bayer

Completed

Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction

Multiple Sclerosis, Relapsing-Remitting

United States
Merck Sharp & Dohme LLC

Completed

Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)

Melanoma
Bayer

Completed

BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program

Relapsing Remitting MS (RRMS) | Secondary Progressive MS (SPMS)

France, Germany, Korea, Republic of, Saudi Arabia, Spain, Taiwan, Czech Republic, Italy, Jordan, Lebanon, Turkey, Israel, Portugal, Netherlands, Iran, Islamic Republic of
Bayer

Completed

BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose (Beyond)

Multiple Sclerosis, Relapsing-Remitting

Belgium, Israel, United States, Canada, France, Switzerland, Ireland, Italy, Australia, Spain, Austria, Germany, Brazil, Netherlands, Poland, Russian Federation, Hungary, Slovenia, Argentina, Ukraine, Greece, Sweden, Finland, Latvia, No... and more
Pfizer

Completed

An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

Dermatomyositis

United States, Spain, Hungary, Poland
Bayer

Completed

Physical Disability in Patients Treated With Betaferon

Multiple Sclerosis

Colombia
Merck KGaA, Darmstadt, Germany

Completed

A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®) (TOURIMS)

Relapsing-Remitting Multiple Sclerosis
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Department of Health, Western Australia

Completed

Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu

Upper Respiratory Tract Infections

Australia
Biogen

Terminated

How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose (TODAY)

Relapsing Remitting Multiple Sclerosis

Australia
OncoCareClinic 308 Ltd

Recruiting

The 1st Tumor CytokinoTherapy Database (TCTD-1)

Oncology

Russian Federation
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia

United States
Seventh Medical Center of PLA General Hospital
The General Hospital of Central Theater Command; The General Hospital of Northern...

Not yet recruiting

To Evaluate the Clinical Efficacy and Safety of Recombinant Human Interferon ω Spray in Treatment of Viral Upper Respiratory Tract Infection in Children

Viral Upper Respiratory Tract Infection
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083)

Melanoma
Icahn School of Medicine at Mount Sinai
Eiger BioPharmaceuticals

Withdrawn

Interferon Lambda Therapy for COVID-19

SARS-CoV-2
Shanghai General Hospital, Shanghai Jiao Tong University...

Completed

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

Recurrence | Hematological Neoplasms

China
Tianjin SinoBiotech Ltd.

Completed

Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient

Hepatitis B Virus

China
Bayer

Completed

BAY86-5046 (Betaseron), Non Interventional Studies (BETAEVAL)

Multiple Sclerosis

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Hoffmann-La Roche

Completed

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Renal Cell Carcinoma | Chronic Myelogenous Leukemia | Malignant Melanoma

Canada, India, Bulgaria, Russian Federation, Spain, South Africa, Slovakia
Huashan Hospital

Unknown

Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy

Chronic Hepatitis B

China
Biogen

Completed

Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers

Multiple Sclerosis

United States
M.D. Anderson Cancer Center

Completed

Pegasys® in Patients With Myeloproliferative Diseases

Myeloproliferative Disorders

United States
M.D. Anderson Cancer Center
Schering-Plough

Terminated

PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron

Leukemia, Myeloid, Philadelphia-Positive

United States
Ochsner Health System
NewLink Genetics Corporation

Unknown

A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma

Melanoma

United States
Bayer

Terminated

Rehabilitation Study in MS Patients

Multiple Sclerosis, Relapsing-Remitting

France
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma

Lymphoma

United States
Biogen

Completed

Immunogenicity and Safety Study of Serum-Free Avonex

Multiple Sclerosis
Merck KGaA, Darmstadt, Germany

Completed

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR)

Relapsing-Remitting Multiple Sclerosis

Germany, Estonia, Latvia, Lithuania, Finland, Austria, Denmark, Netherlands, Portugal, Switzerland, Norway, Italy
Biogen

Withdrawn

Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy (Frequency)

Relapsing Multiple Sclerosis
French National Agency for Research on AIDS and...
Hoffmann-La Roche; InterMune

Completed

Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C

Hepatitis C, Chronic

France
Abramson Cancer Center of the University of Pennsylvania

Completed

IFN-DLI for Relapsed Acute Leukemia After Allo-SCT

Leukemia

United States
Ain Shams University
National Institute of Allergy and Infectious Diseases (NIAID); Beth Israel... and other collaborators

Completed

Timing and Duration of Acute Hepatitis C Treatment

Hepatitis C

Egypt
Nancy Hammond, MD
Kansas City Area Life Sciences Institute, Inc.

Completed

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

Multiple Sclerosis | Low Bone Density

United States
Brii Biosciences Limited
Vir Biotechnology, Inc.

Active, not recruiting

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

Chronic Hepatitis B Virus Infection

Singapore, Thailand, Australia, China, Korea, Republic of
Sheba Medical Center
Tel Aviv Lung Association

Completed

Latent Tuberculosis in Second Generation Immigrants From High Risk Countries Compare to Low-risk Young Israeli Adults

Latent Tuberculosis

Israel
Claudio Gobbi
Bayer

Terminated

Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

Switzerland
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients (SEPTIME)

Multiple Sclerosis, Relapsing, Remitting
AstraZeneca

Completed

A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection (INEXAS)

Asthma

France, United Kingdom, Korea, Republic of, Argentina, Australia, Spain, Colombia
Kyoto University

Completed

Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC

Hepatitis C, Chronic

Japan
HanAll BioPharma Co., Ltd.

Completed

A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, PK/PD, and Preliminary Efficacy Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C

Chronic Hepatitis C Infection | Genotype 1

United States

3

Subscribe